AKBA
Akebia Therapeutics
Stock NASDAQ – Stock Market Prices, News & Analysis
Akebia Therapeutics Inc is dedicated to the development of innovative therapies for individuals affected by kidney disease.
Akebia Therapeutics
AKBA
Akebia Therapeutics Inc is dedicated to the development of innovative therapies for individuals affected by kidney disease.
Price history of Akebia Therapeutics
Price history of Akebia Therapeutics
Performance & Momentum
Piper Sandler Cuts Akebia Target Price Despite Long-Term Upside
Piper Sandler reduced Akebia Therapeutics' (NASDAQ: AKBA) target price to $4 from $6 following a revision of post-2025 estimates. Despite the cut, the analyst maintains an 'Overweight' rating, highlighting strong 20-year growth potential. The company is focusing on expanding U.S. adoption of its VAFSEO anemia treatment and developing a pipeline targeting rare kidney diseases. This update reflects a realignment of expectations with greater emphasis on commercial execution, which may lead to short-term volatility but retains positive medium-term outlooks.
Strategic Analysis
Akebia Therapeutics • 2026
Akebia Therapeutics positions itself as a specialized player in biotechnology, focused on developing innovative treatments for kidney diseases, a medical niche with high unmet needs. Its model relies on targeted research and partnerships centered on differentiated therapies in a highly regulated sector.
Strengths
- Biotechnology expertise centered on a disease with few available therapeutic options
- Valuation potential linked to clinical advancements and strategic partnerships
- Presence in a significant American market, facilitating access to funding and clinical trials
Weaknesses
- High volatility linked to clinical and regulatory risks inherent to biotech
- Past performances marked by high volatility and a recent downward trend
Momentum
The current momentum reflects a challenging phase with notable deterioration over the past six months, indicative of recent operational or market challenges. The medium-term outlook, however, remains supported by a history of progress over several years, warranting strategic vigilance regarding investment timing.
Similar stocks to Akebia Therapeutics
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
